GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 1,078 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $89.44, for a total value of $96,416.32. Following the sale, the chief executive officer now owns 6,674 shares of the company's stock, valued at approximately $596,922.56. The trade was a 13.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Katherine Stueland also recently made the following trade(s):
- On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89.
- On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
- On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
- On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
- On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.
GeneDx Stock Performance
WGS traded up $7.68 during trading hours on Friday, hitting $104.39. 704,762 shares of the stock were exchanged, compared to its average volume of 617,273. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a 12 month low of $8.10 and a 12 month high of $115.60. The stock has a 50-day simple moving average of $84.59 and a 200-day simple moving average of $71.15. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -53.26 and a beta of 1.91.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.
Institutional Trading of GeneDx
Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in GeneDx by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock worth $77,337,000 after buying an additional 156,768 shares during the last quarter. Summit Partners Public Asset Management LLC boosted its holdings in shares of GeneDx by 336.9% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company's stock valued at $58,073,000 after acquiring an additional 582,619 shares during the period. William Blair Investment Management LLC bought a new position in shares of GeneDx during the fourth quarter worth about $51,496,000. Lord Abbett & CO. LLC acquired a new stake in shares of GeneDx in the 4th quarter worth about $48,458,000. Finally, Fred Alger Management LLC boosted its stake in GeneDx by 38.5% during the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company's stock valued at $41,970,000 after purchasing an additional 151,824 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on WGS. The Goldman Sachs Group upped their target price on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen raised their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $72.33.
Check Out Our Latest Analysis on GeneDx
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
